Skip to main content

Table 3 Biomarkers of iodine status

From: The effect of iodine supplementation in pregnancy on early childhood neurodevelopment and clinical outcomes: results of an aborted randomised placebo-controlled trial

 

Iodine

Placebo

Effect (95 % CI)

P value

Cord blood

n = 19

n = 22

  

Free triiodothyronine, pmol/la

2.3 (0.4)

2.3 (0.6)

0.0 (−0.4, 0.3)

0.81

Free thyroxine, pmol/la

14.4 (2.1)

13.8 (2.3)

0.6 (−0.9, 2.2)

0.40

Thyroid-stimulating hormone, mIU/lb

8.2 (5.9–13.5)

6.6 (4.5–9.6)

N/A

0.25

Thyroglobulin, μg/lb

73.0 (48.0–100.0)

64.0 (44.0–121.0)

N/A

0.66

 

(n = 28)

(n = 29)

  

Newborn TSH, mIU/la

2.1 (1.0)

2.2 (1.2)

−0.1 (−0.7, 0.5)

0.79

Newborn TSH > 5c

0 (0.0)

0 (0.0)

N/A

N/A

 

(n = 20)

(n = 25)

  

Breast milk iodine at 6 weeks’ post-partum, μg/lb

106.0 (84.0–146.0)

124.0 (76.0–155.0)

N/A

0.74

  1. CI confidence interval, N/A not applicable, TSH thyroid-stimulating hormone
  2. aData are presented as mean (standard deviation), and the treatment effect is the difference in means
  3. bData are presented as median (interquartile range)
  4. cData are presented as number (percentage)